Solventum Corporation
NYSE:SOLVMedical - Care Facilities
-$2.00 today
- Market cap
- $14.70B
- Beta
- 0.75
- P/E (TTM)
- 9.1
- EPS (TTM)
- $8.22
Volume 0.76M
Average 1.70M
SOLV Deferred Income Tax
The difference between tax expense recognized and tax actually paid in cash during the period.
Solventum CorporationNYSE: SOLV
Deferred Income Tax · Q2 FY2026 · quarter ended Jun 2026
Deferred income tax growth accelerates
Q2 FY2026 deferred income tax of $47M (cash outflow) rose 42.4% year over year, ahead of the -88.8% change in trailing-twelve-month deferred income tax. Sequentially, it rose 14.6% from the prior quarter. Over 3 fiscal years it compounded at -5.2% a year.
Context
- Deferred income tax amounted to 1.4% of revenue in FY2025, down 0.4 pp from a year earlier.
- Deferred income tax grew in size in 2 of the last 3 fiscal years.
- FY2025 was the smallest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +42.4% holds above the trailing-twelve-month pace of -88.8%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Deferred Income Tax history
USD · from the cash flow
- Latest · FY2025
- (120M) USD
- Year-over-year change
- +22.6%
| Period | Period end | Deferred Income Tax | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (120M) | +22.6% |
| FY2024 | 2024-12-31 | (155M) | -9.2% |
| FY2023 | 2023-12-31 | (142M) | -0.7% |
| FY2022 | 2022-12-31 | (141M) | -314.7% |
| FY2021 | 2021-12-31 | (34M) | — |
Deferred Income Tax vs competitors
How SOLV compares with its peers on the latest reported figures
- SOLV's LTM Jun 2026 deferred income tax of $31M is the 4th largest of the 10 companies compared; the peer median is $0.
- Its year-over-year change of -88.8% is the 7th highest of 8, against a peer median of +30.9%.
- Deferred income tax amounts to 0.4% of revenue for SOLV, versus a peer median of 0.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $237M | +170.7% | — | 2.1% | |
| LTM Sep 2026 | $89M | +30.9% | — | 0.4% | |
| LTM Jul 2026 | $43.2M | -82.1% | +35.9% | 1.0% | |
| LTM Jun 2026 | $31M | -88.8% | -5.2% | 0.4% | |
| LTM Mar 2026 | $31M | -75.4% | — | 0.8% | |
| LTM Oct 2026 | $14M | -132.4% | — | 0.5% | |
| LTM Jun 2026 | $7M | +114.6% | — | 0.1% | |
| LTM Sep 2026 | $5.21M | — | — | 0.3% | |
| LTM Mar 2026 | $589K | +61.8% | +18.0% | 1.6% | |
| LTM Jun 2026 | $0 | — | — | 0.0% | |
| Peer median (excluding SOLV) | $0 | +30.9% | +26.9% | 0.5% | |
Competitors are the stored peer set for SOLV. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 1.46B | 1.34B | 1.35B | 479M | 1.56B |
| Depreciation & Amortization | 597M | 578M | 561M | 555M | 489M |
| Deferred Income Tax | (34M) | (141M) | (142M) | (155M) | (120M) |
| Stock-Based Compensation | 38M | 37M | 39M | 112M | 161M |
| Change in Working Capital | 67M | (202M) | 126M | 160M | (119M) |
| Accounts Receivables | (1M) | (32M) | (129M) | 276M | 78M |
| Inventory | (136M) | (82M) | 23M | (132M) | (139M) |
| Accounts Payables | 68M | 25M | 105M | 266M | 104M |
| Other Working Capital | 136M | (113M) | 127M | (250M) | (162M) |
| Other Non-Cash Items | 74M | 64M | (15M) | 34M | (1.6B) |
| Operating Cash Flow | 2.2B | 1.68B | 1.92B | 1.19B | 369M |
| Capital Expenditures | (277M) | (251M) | (290M) | (380M) | (379M) |
| Acquisitions (Net) | 0 | 0 | 60M | 0 | (696M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | (1M) | (2M) | 0 | 0 | 3.87B |
| Investing Cash Flow | (278M) | (253M) | (230M) | (380M) | 2.8B |
| Debt Repayment | 0 | 0 | 0 | 8B | (3.07B) |
| Common Stock Issued | 0 | 0 | 0 | 0 | 0 |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (1.96B) | (1.46B) | (1.55B) | (8.24B) | 13M |
| Financing Cash Flow | (1.96B) | (1.46B) | (1.55B) | (240M) | (3.06B) |
| Effect of Forex Changes | 3M | 4M | 0 | 3M | 7M |
| Net Change in Cash | (33M) | (30M) | 133M | 568M | 116M |
| Free Cash Flow | 1.93B | 1.43B | 1.63B | 805M | (10M) |
Solventum Corporation
NYSE:SOLV
Intrinsic Alpha fair value
Locked
Current Price
$86.48
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.